[1]耿肖囡 肖东斌 魏鑫 惠学志.达格列净对心血管疾病的预防保护机制[J].心血管病学进展,2019,(8):1169-1171.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
 GENG Xiaonan,XIAO Dongbin,WEI xin,et al.Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1169-1171.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
点击复制

达格列净对心血管疾病的预防保护机制()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年8期
页码:
1169-1171
栏目:
综述
出版日期:
2019-11-25

文章信息/Info

Title:
Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease
作者:
耿肖囡 肖东斌1 魏鑫1 惠学志
(1.河南大学研究生院,河南 开封 475000; 2.河南大学第一附属医院心血管内科,河南 开封 475000)
Author(s):
GENG Xiaonan1 XIAO Dongbin1WEI xin1HUI Xuezhi2
(1.Henan University Graduate School,Kaifeng 475000,Henan,China; 2. Department of Cardiology, The First Affiliated Hospital of Henan University, Kaifeng 475000,Henan,China)
关键词:
钠-葡萄糖协同转运蛋白2抑制剂达格列净心血管疾病2型糖尿病
Keywords:
Sodium-glucose cotransporter 2 inhibitorDagliflozinCardiovascular diseasesType 2 diabetes
DOI:
10.16806/j.cnki.issn.1004-3934.2019.08.025
摘要:
钠-葡萄糖协同转运蛋白2抑制剂是一种新型的降糖药物,其抑制钠-葡萄糖协同转运蛋白2的作用机制不同于以往的降血糖药物。以达格列净为代表的该类药物在降低血糖的同时兼具降脂、降压、肾脏保护等多方面的获益,达格列净可在一定程度上干预降低2型糖尿病患者心血管事件的发生和发展。其在降血糖以外对心血管的保护作用方面展现出特殊的优势,现就钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者的心血管保护及心血管事件危险因素的预防机制做一综述。
Abstract:
The sodium-glucose cotransporter 2(SGLT-2) inhibitor is a novel hypoglycemic agent , and its role mechanism of inhibit ing SGLT-2 is different from previous hypoglycemic agents. This type of drug, represented by dagliflozin, has both benefits in reducing blood sugar and benefits such as reducing fat, reducing blood pressure, and protecting the kidneys. Dagliflozin can intervene to reduce the incidence and development of cardiovascular events in patients with type 2 diabetes to some extent . It has a special advantage in protecting the cardiovascular system from hypoglycemia. This article reviews the effect of SGLT-2 inhibitor in cardiovascular protection and the prevention mechanism of cardiovascular risk factors for type 2 diabetes patients.

参考文献/References:

[1] Peet MM. Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy[J]. Am J Surg ,1948,75(1):48-68.

[2] Fox CS,C oady S,Sorlie PD,et al. Increasing cardiovascular disease burden due to diabetes mellitus - The Framingham Heart Study[J]. Circulation,2007,115(12):1544-1550.

[3] Davies MJ,D’alessio DA,F radkin J,et al. Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetes Care,2018,41(12):2669-2701.

[4] Meng W,E llsworth BA,N irschl AA,et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes[J]. J Med Chem,2008,51(5):1145-1149.

[5] DeFronzo RA,Davidson JA,del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia[J]. Diabetes Obes Metab,2012,14(1):5-14.

[6] Imprialos KP,Sarafidis PA, Karagiannis AI. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?[J]. J Hypertens,2015,33(11):2185-2197.

[7] Karg MV,Bosch A,Kannenkeril D,et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content:a randomised controlled trial[J]. Cardiovasc Diabetol,2018,17 (1):5.

[8] Matthews VB,Elliot RH,Rudnicka C,et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2[J]. J Hypertens,2017,35(10):2059-2068.

[9] Han JH,Oh TJ,Lee G,et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE(-/-) mice fed a western diet[J]. Diabetologia,2017,60(2):364-376.

[10] Hayashi T,Fukui T,Nakanishi N,et al. Correction to: dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin[J]. Cardiovasc Diabetol,2017,16(1):149.

[11] Inzucchi SE,Zinman B,Wanner C,et al. SGLT-2 inhibitors and cardiovascular risk:proposed pathways and review of ongoing outcome trials[J]. Diab Vasc Dis Res,2015,12(2):90-100.

[12] Li T,Zhang Z,Kolwicz SC,et al. Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion Injury[J]. Cell Metab,2017,25(2):374-385.

[13] Bertero E,Prates roma L,Ameri P,et al. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis[J]. Cardiovasc Res,2018,114(1):12 -18.

[14] Ndrepepa G. Uric acid and cardiovascular disease[J]. Clin Chim Acta,2018,484:150-163.

[15] Chino Y,Samukawa Y,Sakai S,et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria[J]. Biopharm Drug Dispos,2014,35(7):391-404.

[16] Terami N,Ogawa D,Tachibana H,et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor,dapagliflozin,ameliorates glucose homeostasis and diabetic nephropathy in db/db mice[J]. PLoS One,2014,9(6):e100777.

[17] Bloomgarden Z. The kidney and cardiovascular outcome trials[J]. J Diabetes,2018,10(2):88-89.

[18] Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus[J]. Annu Rev Med,2015,66:255-270.

[19] Saleem F. Dapagliflozin: cardiovascular safety and benefits in type 2 diabetes mellitus[J]. Cureus,2017,9(10):e1751.

[20] 高斯德,李卫萍,李虹伟. 钠-葡萄糖协同转运蛋白抑制剂与心力衰竭的研究进展[J]. 心血管病学进展,2018,39,(5):703-708.

[21] Verma S,Mazer CD,Fitchett D,et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME(?) randomised trial[J]. Diabetologia,2018,61(8):1712-1723.

[22] Fox CS,Golden SH,Anderson C,et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association[J]. Diabetes Care,2015,38(9):1777-1803.

相似文献/References:

[1]王菲 卢新政.卡格列净对2型糖尿病患者心血管保护作用的研究进展[J].心血管病学进展,2020,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
 WANG Fei,LU Xinzheng.Cardiovascular Protection of Canagliflozin in Type 2 Diabetes Patients[J].Advances in Cardiovascular Diseases,2020,(8):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
[2]辛玉晶,刘昊凌.钠-葡萄糖协同转运蛋白2抑制剂与2型糖尿病心血管危险因素的研究进展[J].心血管病学进展,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
 XIN Yujing,LIU Haoling.SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(8):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
[3]张阳扬 尹德录.新型降糖药物在心力衰竭中的应用前[J].心血管病学进展,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
 ZHANG Yangyang,YIN Delu.Prospect of New Glucose-lowering Drugs in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(8):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
[4]游月婷 汪汉 徐俊波.达格列净在心力衰竭治疗中的研究进展[J].心血管病学进展,2020,(8):830.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.012]
 YOU Yueting,WANG Han,XU Junbo.Dapagliflozin in the Treatment of Heart Failure[J].Advances in Cardiovascular Diseases,2020,(8):830.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.012]
[5]张欣 郭艺芳.钠-葡萄糖协同转运蛋白2抑制剂相关心血管益处的可能潜在机制[J].心血管病学进展,2020,(9):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]
 ZHANG Xin,GUO Yifang.Potential Mechanisms of Sodium-glucose Co-transporter 2 Inhibitor-related Cardiovascular Benefits[J].Advances in Cardiovascular Diseases,2020,(8):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]
[6]和丽丽 左庆娟 张国瑞 郭艺芳.钠-葡萄糖协同转运蛋白2抑制剂使心力衰竭获益的作用机制[J].心血管病学进展,2020,(9):954.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.017]
 HE Lili,ZUO Qingjuan,ZHANG Guorui,et al.Mechanism of Benefit of Sodium-glucose Co-transporter 2 Inhibitors in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(8):954.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.017]
[7].钠-葡萄糖协同转运蛋白2抑制剂获益的研究进展及指南推荐050011;.河北省人民医院老年心血管内科,河北 石家庄 050051)[J].心血管病学进展,2021,(3):252.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.015]
 Cardiology Department,The Third Hospital of Shijiazhuang City Affiliated to Hebei Medical University,Shijiazhuang 000,et al.Research Progress and Guideline Recommendations of Cardiovascular Benefits of SGLT-2 Inhibitors[J].Advances in Cardiovascular Diseases,2021,(8):252.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.015]
[8]杨宜恒 郑振中.钠-葡萄糖协同转运蛋白2抑制剂对于未合并2型糖尿病的心力衰竭患者治疗的研究进展[J].心血管病学进展,2021,(12):1093.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.009]
 YANG Yiheng,ZHENG Zhenzhong.Treatment of Sodium-Glucose Co-Transporter 2 Inhibitor in Patients with Heart Failure without Type 2 Diabetes[J].Advances in Cardiovascular Diseases,2021,(8):1093.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.009]
[9]张敏 龙开超 唐毅 刘君宇 彭建强.钠-葡萄糖协同转运蛋白2抑制剂使心力衰竭获益机制研究进展[J].心血管病学进展,2021,(12):1096.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.010]
 ZHANG Min,LONG Kaichao,TANG Yi,et al.Mechanism of the Benefit of Sodium-Glucose?o-Transporter 2 Inhibitors in Heart Failure[J].Advances in Cardiovascular Diseases,2021,(8):1096.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.010]

更新日期/Last Update: 2020-03-02